ClinicalTrials.gg
RecruitingNCT04559373Updated Oct 7, 2026

Virtual Reality and Field Training to Enhance Community Walking After Stroke

An interventional study of Virtual Reality and Field Training (VRFT) in Stroke, sponsored by McGill University. Recruiting at 2 sites in Canada. Open to participants aged 40 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by McGill University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.
Updated Oct 7, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
40 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Stroke by McGill University — 7 open to participants now, 7 under way, none of them phase 3. Stroke · McGill University.

Planned enrollment
8th of 15
40 · median 40
Started
2021
with 2 others
No phase
15 of 16
6 open now
Registered
8th of 16
by date

Among the 16 studies in Stroke by McGill University, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2021, is one of 15 with no phase, and was the 8th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

7 of the 16 studies in Stroke by McGill University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 40 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Stroke by McGill University, or all of them as a file.
02

Study summary

While stroke survivors discharged from rehabilitation present with some recovery in mobility, their ability to ambulate in the community remains limited. The investigators propose to test a novel, low-cost, intensive and individually tailored intervention that combines virtual reality (VR) and field training to enhance community ambulation and participation in stroke survivors discharged from rehabilitation.

The aims are to: (1) Assess feasibility, acceptability, safety and adherence of the intervention in stroke survivors; and (2) Examine the extent to which post-intervention changes in functional walking and participation to community walking vary according to walking, cognitive and visual-perceptual abilities.

The investigators will use a virtual environment prototype simulating a shopping mall and surrounding streets, in which participants will interact using VR goggles and game controllers. Scenarios of increasing levels of complexity will be introduced. This intervention study involves a single group, multiple pre- multiple post- study design where chronic stroke participants will engage in a 4-week training program. The program will include VR training sessions performed in the clinical setting (3/week) and practice of community ambulation skills while supervised by family/caregivers (2/week). Participants will be assessed on measures of functional walking, balance \& mobility and participation to community walking. Adherence, safety and acceptability will be documented. This study will generate foundation knowledge on the response to the intervention based on individual capacities.

Read the detailed description

Ambulating in community environments requires the skills to cope with multiple, simultaneous dimensions such as walking speed and distance, etc. Such skills remain compromised in the majority of stroke survivors due to insufficient or lack of targeted practice. The investigators propose to test a new, individually-tailored intervention, developed by the research team, grounded in best evidence in community ambulation, principles of motor learning and participatory action research. This unique intervention will combine virtual reality (VR) and field training practice to optimize learning that can be generalized to daily walking activities.

Participants will engage in the 4-week, individually-tailored intervention that comprises of supervised VR training sessions (3 times/week) performed in the clinical setting. VR sessions will be completed by field training assignments. Subjects will be assessed twice prior to the intervention, immediately after the intervention and at follow up.

Generalized estimating equations will be used to compare changes in main and secondary outcomes across time points, with each personal factor of interest (e.g. walking capacity, visual-perceptual function, and cognitive function) analyzed individually while adjusting for age. Outcomes on adherence, safety and acceptability will be analyzed with descriptive statistics.

Required sample size was estimated based on Green's rule (effect size=0.5, power=80%, α=0.05) with a variance inflation factor assuming moderate within-subject correlations for 3 post-baseline measurement time points. This yields a sample size of 30. Assuming a worst-case scenario of 30% attrition rate, a total of 40 stroke subjects (20/site) will be recruited.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Aging
  • Biomechanics
  • Community ambulation
  • Intervention
  • Locomotion
  • Rehabilitation
  • Sensorimotor integration
  • Virtual reality
04

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

People with chronic stroke and persistent deficits in walking / visual-perceptual / cognitive capacities. They can be male or female, aged from 40 to 74 years, with normal/corrected visual and auditory acuity, and present with:

  • First-ever supratentorial unilateral stroke 9-24 months ago (such chronicity will ensure steady-state mobility without long-term disuse-related changes
  • Mild-to-moderate hemiparesis (Chedoke McMaster Stoke Assessment stages 4/7-6/7 on postural control, leg \& foot)
  • Ability to walk independently with/without walking aids for at least 1 min at 0.4-0.9 m/s (such a speed range indicates mobility not sufficient for functional community ambulation: shopping \~1.1m/s, street crossing \~1.2 m/s)
  • Intact or mildly affected cognitive function ( scores ≥ 22/30)
  • Intact to moderately affected visual-perceptual function (positive scores on a maximum of 3/6 tasks on the Behavioural Inattention Test)

Exclusion criteria

Exclusion Criteria:

  • Subjects with comorbidities interfering with walking
  • Subjects with comorbidities interfering with visual perception
  • Subjects without medical clearance for exercise
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Virtual Reality and Field Practice Training (VRFT)

    Participants will engage in a 4-week VRFT intervention that comprises of 1-hour training sessions, 3 times/week.

    Other: Virtual Reality and Field Training (VRFT)

Interventions

  • OtherVirtual Reality and Field Training (VRFT)

    The VRFT intervention involves the intensive practice of community ambulation skills. Some of the training sessions will be performed in a virtual environment, while others will consist of field training exercises in the community. During the intervention, stroke participants will be invited to practice different dimensions of community ambulation, such as postural transitions, avoiding other pedestrians, dual-task walking, etc.

06

What researchers measure

Primary outcomes

  1. Post-intervention change in the Six Minute Walk Test (6MWT)

    The six-minute walk test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.

    Time frame: Pre-intervention (Week4) and post-intervention (Week8)

  2. Change in the Six Minute Walk Test (6MWT) at Follow-up

    The six-minute walk test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.

    Time frame: Post-intervention (Week8) and Follow-up (Week12)

Secondary outcomes

  1. Dynamic Gait Index

    Developed to assess the likelihood of falling in older adults

    Time frame: Baseline (Week0), pre-intervention (Week4), post-intervention (Week8) and follow-up (Week12)

  2. 5m Walk Test

    Assesses walking speed in meters per seconds over a short duration

    Time frame: Baseline (Week0), pre-intervention (Week4), post-intervention (Week8) and follow-up (Week12)

  3. Activities-Specific Balance Confidence Scale

    16-item self-reported measure of balance confidence performing various activities without losing balance or experiencing a sense of unsteadiness. Items are rated on a 0%-100% response scale, with a score of 0 representing no confidence and a score of 100 representing complete confidence.

    Time frame: Baseline (Week0), pre-intervention (Week4), post-intervention (Week8) and follow-up (Week12)

  4. Trip Activity Log

    Questionnaire to record the number of trips and walking-related activities in the community (e.g. outside home) 3 days preceding its administration

    Time frame: Baseline (Week0), pre-intervention (Week4), post-intervention (Week8) and follow-up (Week12)

  5. Environmental Analysis of Mobility Questionnaire

    Self-reported tool to assess mobility problems due to the environment

    Time frame: Baseline (Week0), pre-intervention (Week4), post-intervention (Week8) and follow-up (Week12)

  6. Assessment of Life Habits (Life-H: mobility and community life domains)

    Assesses mobility and community life habits based on the levels of accomplishment and assistance required as well as satisfaction

    Time frame: Baseline (Week0), pre-intervention (Week4), post-intervention (Week8) and follow-up (Week12)

Other outcomes

  1. Adherence to intervention

    Training logbook filled by researchers/clinicians (virtual reality) and subjects (field training) component)

    Time frame: 3x/week over the 4-week intervention for the virtual reality component; 2x/week over the 4-week intervention for the field training component

  2. Safety of the intervention

    Assesses by systematically collecting any occurrence of adverse/unwanted events (falls, injuries, fatigue, etc).

    Time frame: 3x/week over the 4-week intervention of the virtual reality component

  3. Acceptability of the intervention

    Assesses using the Technology Acceptance Model based Questionnaire (Tam-Q) based on the technology acceptance model, in which subjects will rate their perception on each dimension using a visual analog scale ranging from 0-56, with higher score representing higher acceptance to the intervention.

    Time frame: Post-intervention (Week8)

  4. Cadence

    Cadence is the rate at which a person walks (steps per minute) and will be measured with the GaitRite system.

    Time frame: Pre-intervention (Week4) and post-intervention (Week8)

  5. Step length

    Step length is the distance (in meters) from a point of contact with the ground of one foot to the following occurrence of the same point of contact with the other foot and will be measured with the GaitRite system.

    Time frame: Pre-intervention (Week4) and post-intervention (Week8)

  6. Step duration

    Step duration is the period of time (in seconds) taken for one step is measured from an event of one foot to the following occurrence of the same event with the other foot and will be measured with the GaitRite system.

    Time frame: Pre-intervention (Week4) and post-intervention (Week8)

  7. Stance phase

    Stance phase is the period of time when the foot is in contact with the ground (%) and will be measured with the GaitRite system.

    Time frame: Pre-intervention (Week4) and post-intervention (Week8)

  8. Swing phase

    Swing phase is the period of time when the foot is not in contact with the ground (%) and will be measured with the GaitRite system.

    Time frame: Pre-intervention (Week4) and post-intervention (Week8)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data for all primary and secondary outcome measure will be made available.

Time frame: Data will be available within 6 months of study completion

Access criteria: De-identified data will be deposited in a REDCap database and made available to collaborators. Data may also be made available to other researchers via an institutional data repository that will allow adhering to FAIR principles.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for May 2027, 73 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 73 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion May 2026 → May 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2020
First posted
Sep 22, 2020
StartActual
Apr 1, 2021
Primary completionEst.
May 31, 2027was May 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 31, 2026→May 31, 2027
Oct 7, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Oct 7, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Jewish Rehabilitation Hospital · Laval, CanadaContact v•••@ssss.gouv.qc.ca · •••9550→v•••@ssss.gouv.qc.ca · •••9550
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Primary completion May 31, 2026→May 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Jewish Rehabilitation Hospital · Laval, CanadaContact v•••@ssss.gouv.qc.ca · •••9550→v•••@ssss.gouv.qc.ca · •••9550

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04559373
Lead sponsor
McGill University
Collaborators
Jewish Rehabilitation Hospital, Integrated University Health and Social Services Center of the Capitale-Nationale, Laval University
Responsible party
Anouk Lamontagne (Associate Professor, McGill University) — Principal investigator
First posted
Sep 22, 2020
Start date
Apr 1, 2021
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Anouk Lamontagne, PhD
Contact
anouk.lamontagne@mcgill.ca
514-938-4397
Andréanne Blanchette, PhD
Contact
andreanne.blanchette@fmed.ulaval.ca
418-656-2131 ext. 403579
Anouk Lamontagne, PhD
principal investigator · McGill University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion